Cardiomatics is an innovative Polish health tech company focused on leveraging AI to automate and enhance ECG analysis in cardiology. The company has demonstrated rapid product innovation, strong regulatory compliance, and a growing international presence in clinical practice and research.
Cardiomatics offers a SaaS cloud platform for automated long-term ECG interpretation and arrhythmia diagnostics, compatible with multiple devices and data formats.
Headquarters: Krakow, Poland.
Founded in 2018 by Rafał Samborski (PhD, electronics), with a strong technical/academic team.
The initial product focuses on leveraging advanced digital signal processing and deep learning to support clinical decision-making in cardiology.
Raised $3.2 million in seed funding (2021), led by Kaya VC, with additional participation from Nova Capital, Innovation Nest, and Nina Capital; includes a $1 million R&D grant.
Dealroom estimates the enterprise valuation to be between $9-$13 million as of 2021.
Total funding over two rounds reached approximately $3.5 million.
AI-powered cloud software for automated Holter ECG analysis and diagnostic report generation.
Device-agnostic platform (compatible with 40+ recorders).
Arrhythmia detection, real-time ECG analysis, personalized health insights, remote monitoring, and diagnostic metrics (e.g., AV block detection, atrial fibrillation burden).
Report delivery within minutes, reducing review workload by up to 80%.
v5 (2023) introduced automated 2nd and 3rd-degree AV block detection and “fast-track” priority analysis options for urgent cases.
Continual updates to report layout and workflow features improve speed, critical insight display, and clinical value.
Culture prioritizes innovation, skill development, teamwork, and empowering physicians with technology for better cardiac care.
Employees benefit from equity participation, training budgets, private healthcare, and a supportive, mission-driven environment.
User base: Over 1,000 clinics in 15+ countries; includes major university hospitals, independent practices, and research centers in Germany, Switzerland, UK, and Poland.
Community: Includes both clinical users (cardiologists, general practitioners) and researchers; actively partners with device manufacturers and medical organizations for product ecosystem expansion and early AI adoption.
Subscription and pay-per-use pricing models cater to both small practices and larger organizations.
